Management of Small Pancreatic Cystic Lesions

Risk Assessment for Pancreatic Cystic Lesions

The absence of worrisome features in small pancreatic cystic lesions indicates a very low risk of malignancy, according to the European guidelines 1, 2
The risk of malignancy in pancreatic cystic lesions increases significantly with certain features, such as cyst size ≥30 mm 2
The presence of enhancing mural nodules is a risk factor for malignancy in pancreatic cystic lesions 2
Main pancreatic duct dilation ≥5 mm is a risk factor for malignancy in pancreatic cystic lesions 3

The European guidelines recommend MRI with MRCP as the preferred imaging modality for surveillance of small pancreatic cystic lesions 3, 4
First follow-up imaging should be performed in 1 year to assess for stability, according to the Praxis Medical Insights guidelines 5

If the cysts remain stable after the first year, subsequent imaging can be performed every 2 years for a total of 5 years, as recommended by the Praxis Medical Insights guidelines 5
The European guidelines recommend continued surveillance as long as the patient remains fit for surgery, as the risk of progression increases over time 2

Immediate further evaluation with EUS-FNA would be indicated if any of these changes occur during follow-up, such as growth rate ≥5 mm/year 2
Development of solid components or mural nodules is an indication for further evaluation with EUS-FNA 1, 2
Main pancreatic duct dilation ≥5 mm is an indication for further evaluation with EUS-FNA 3
Cyst size reaching ≥30 mm is an indication for further evaluation with EUS-FNA 5, 4

The risk of adverse events from EUS-FNA (3.4%) may outweigh benefits for very small cysts without worrisome features, according to the Gut guidelines 1
Failing to establish an appropriate surveillance plan can lead to unnecessary procedures with associated risks, as even small cysts have a small risk of progression over time 2
The patient's age should be considered in the surveillance plan, as pancreatic cystic lesions have a slow growth rate, and the risk-benefit ratio of aggressive management may not favor intervention in older patients 5

Initial MRI with MRCP at 1 year from detection is recommended by the Praxis Medical Insights guidelines 5, 3
If stable and remaining <5 mm without developing worrisome features, continue MRI surveillance every 2 years for at least 5 years, as recommended by the Praxis Medical Insights guidelines 5
If growth occurs but remains <30 mm without other worrisome features, continue surveillance with shortened interval (yearly), according to the European guidelines 2
If growth ≥5 mm/year, size reaches ≥30 mm, or development of any worrisome features, proceed to EUS-FNA for further evaluation, as recommended by the Gut guidelines 1, 2, 5